KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).

Junjie Li, Feng Wei, Peng Xiang, Zhengang Tang, Lianshu Ding, Luke Francis Chen, Maria Losada, Zlatka Iamboliyska, Fang Sun, Mingfen Zhu, Xiaodan Guo, Xiaoling Du, Chang Chen, Christopher Bruno, Sandra Koseoglu, Katherine Young, Min Zhou, Jieming Qu

Int J Infect Dis 153 107357

PMID39674398
PMCID-
DOI10.1016/j.ijid.2024.107357
发表日期2024-12-14
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVES: Imipenem/cilastatin/relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor combination effective against gram-negative pathogens. Efficacy and safety of IMI/REL were studied in critically ill adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). METHODS: In this phase III, double-blind, multinational, randomized trial (NCT03583333), adults with HABP/VABP were randomized 1:1 to receive intravenous IMI/REL (500 mg/250 mg) or piperacillin/tazobactam (PIP/TAZ; 4000 mg/500 mg) every 6 h for 7-14 days. The primary endpoint was 28-day all-cause mortality (ACM). Secondary endpoints were clinical response (CR), microbiological response (MR), and adverse event (AE) incidence. RESULTS: In the modified intention-to-treat population (N = 270 [IMI/REL: n = 134; PIP/TAZ: n = 136]), demographics and baseline characteristics were comparable between treatment groups. Most patients were from China. IMI/REL was noninferior to PIP/TAZ for 28-day ACM (11.2% vs 5.9%; adjusted difference [95% confidence interval]: 5.2% [-1.5 to 12.4]). Secondary outcomes were comparable between treatment groups, including favorable CR and MR. AEs resulting in death were generally consistent with pre-existing or underlying illness. CONCLUSIONS: IMI/REL met noninferiority criteria vs PIP/TAZ for 28-day ACM, and safety profiles were comparable. This trial could support the use of IMI/REL to treat adults with HABP/VABP, including regional use in China.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。